Skip to main content
. Author manuscript; available in PMC: 2014 Aug 6.
Published in final edited form as: Pediatr Blood Cancer. 2012 Jan 31;59(4):717–724. doi: 10.1002/pbc.24096

Fig. 1.

Fig. 1

Quality-adjusted life years (QALYs) and days (QALDs) lost by ALL patients during active treatment phases according to HUI2 and HUI3 systems. During induction, CNS and intensification treatment phases there were no differences in mean HRQL scores between E. coli and Erwinia asparaginase treatment groups so the results for these 3 phases are based on pooled data from both groups. During continuation there were significant differences in mean HRQL between the asparaginase groups so the results for this phase are based on data from only the E.coli group.